[{"orgOrder":0,"company":"MaxCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"MCY-M11","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Not Applicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"APN401","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ APEIRON","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ APEIRON"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"MCY-M11","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Not Applicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"MCY-M11","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase I","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"MaxCyte \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MaxCyte \/ Not Applicable"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Intima Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"CISH","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MaxCyte \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"MaxCyte \/ MaxCyte"},{"orgOrder":0,"company":"MaxCyte","sponsor":"LG Chem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"LR19023","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ LG Chem","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ LG Chem"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MaxCyte \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"MaxCyte \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Curamys","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Curamys","highestDevelopmentStatusID":"1","companyTruncated":"MaxCyte \/ Curamys"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Catamaran Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"CAR-NK Cell Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Catamaran Bio","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Catamaran Bio"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Walking Fish Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"B Cell-based Therapeutic","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Walking Fish Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ Walking Fish Therapeutics"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Vittoria Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Viper 101","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Vittoria Biotherapeutics","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Vittoria Biotherapeutics"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Prime Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Genetic Therapy","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Prime Medicine","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ Prime Medicine"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Lion TCR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"TCR-T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Lion TCR","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ Lion TCR"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MaxCyte \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"MaxCyte \/ MaxCyte"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Wugen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"WU-CART-007","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MaxCyte \/ Wugen","highestDevelopmentStatusID":"7","companyTruncated":"MaxCyte \/ Wugen"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Be Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"B Cell-based Therapy","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"MaxCyte \/ Be Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Be Biopharma"}]

Find Clinical Drug Pipeline Developments & Deals by MaxCyte

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Be Bio gains non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform to support the development of its BCMs programs.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 02, 2024

                          Lead Product(s) : B Cell-based Therapy

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Be Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Wugen gains non-exclusive clinical and commercial rights to MaxCyte’s Flow Electroporation® technology to support programs like WU-CART-007 for hematologic and solid tumors.

                          Brand Name : WU-CART-007

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 30, 2024

                          Lead Product(s) : WU-CART-007

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Wugen

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Imugene has obtained commercial rights to use MaxCyte’s technology and ExPERT platform to support azer-cel, a potential allogeneic CD19 CAR T product candidate for blood cancer treatment.

                          Brand Name : PBCAR0191

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 23, 2024

                          Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Imugene

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, Lion TCR obtains worldwide non-exclusive rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform for developing new TCR-T cell therapies for solid tumors.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 03, 2024

                          Lead Product(s) : TCR-T Cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Lion TCR

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, Prime Medicine obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, to develop a new class of differentiated, one-time, potentially curative genetic therapi...

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          August 01, 2023

                          Lead Product(s) : Genetic Therapy

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Discovery Platform

                          Sponsor : Prime Medicine

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Vittoria will obtain rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform which will support its Senza5 technology to enhance efficacy of T-cell therapies including, Viper 101, a gene-edited, autologous, dual-population cell ther...

                          Brand Name : Viper 101

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 10, 2023

                          Lead Product(s) : Viper 101

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Vittoria Biotherapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the agreement, Walking Fish will use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 04, 2023

                          Lead Product(s) : B Cell-based Therapeutic

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery Platform

                          Sponsor : Walking Fish Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : CAT-248 is a CAR-NK cell therapy targeting CD70 positive tumors. CAT-248 has been engineered with four functional modifications: an optimized CAR that targets CD70, an IL-15 cytokine, a TME-switch, and the elimination of CD70 expression to enable scalabl...

                          Brand Name : CAT-248

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          January 03, 2023

                          Lead Product(s) : CAR-NK Cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Catamaran Bio

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          09

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, Curamys obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 05, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Curamys

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          10

                          Fi Europe 2024
                          Not Confirmed
                          Fi Europe 2024
                          Not Confirmed

                          Details : Under the terms of the agreement, Vertex obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform in the development of its CRISPR/Cas9-based gene-edited therapy (exa-cel, formerly k...

                          Brand Name : Exa-cel

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 28, 2022

                          Lead Product(s) : Exagamglogene Autotemcel

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Vertex Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank